Frontiers in immunology · 2026
A C57BL/6N mice model of CP/CPPS established by prostate antigen immunization with DPT and BCG co-administration.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Guan Yu, Cheng Andong, Chen Yiding, Li Hao, Yang Feixiang, Hao Wenbo, Wang Qiangsheng, Liang Chaozhao, Meng Jialin
Аннотация
BACKGROUND AND OBJECTIVE: Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) is common in young and middle-aged men, but existing animal models have key limitations. We aimed to establish a C57BL/6N mice model for mechanistic studies of CP/CPPS.
METHODS: We immunized C57BL/6N mice with prostate antigen plus complete Freund's adjuvant and added DPT, BCG, or DPT+BCG according to group assignment. Von Frey testing, ELISA, flow cytometry, HE staining, and immunohistochemistry were performed to assess pain, cytokines, immune cells, and prostate pathology.
KEY FINDINGS AND LIMITATIONS: PAg+CFA+DPT+BCG booster immunization induced the strongest pain-related phenotype, increased IL-1β and TNF-α levels, reduced IL-10, aggravated prostatic inflammation, and increased NLRP3, COX-2, NF-κB, and Caspase-1 expression compared with the NC group. Compared with either monotherapy, the PAg+CFA+DPT+BCG group showed stronger inflammatory and pain-related phenotypes across most readouts. Limitation: The model does not fully replicate human CP/CPPS heterogeneity.
CONCLUSIONS AND CLINICAL IMPLICATIONS: We established a C57BL/6N mice model with CP/CPPS-like inflammatory and pain-related features and found that DPT+BCG co-administration produced the strongest phenotype. Its compatibility with transgenic mice may facilitate mechanistic studies and preclinical hypothesis testing in CP/CPPS.
PATIENT SUMMARY: In this study, we established a prostatitis-like model in C57BL/6N mice. Booster immunization with DPT+BCG induced inflammatory and pain-related changes, providing a useful model for future mechanistic studies.
METHODS: We immunized C57BL/6N mice with prostate antigen plus complete Freund's adjuvant and added DPT, BCG, or DPT+BCG according to group assignment. Von Frey testing, ELISA, flow cytometry, HE staining, and immunohistochemistry were performed to assess pain, cytokines, immune cells, and prostate pathology.
KEY FINDINGS AND LIMITATIONS: PAg+CFA+DPT+BCG booster immunization induced the strongest pain-related phenotype, increased IL-1β and TNF-α levels, reduced IL-10, aggravated prostatic inflammation, and increased NLRP3, COX-2, NF-κB, and Caspase-1 expression compared with the NC group. Compared with either monotherapy, the PAg+CFA+DPT+BCG group showed stronger inflammatory and pain-related phenotypes across most readouts. Limitation: The model does not fully replicate human CP/CPPS heterogeneity.
CONCLUSIONS AND CLINICAL IMPLICATIONS: We established a C57BL/6N mice model with CP/CPPS-like inflammatory and pain-related features and found that DPT+BCG co-administration produced the strongest phenotype. Its compatibility with transgenic mice may facilitate mechanistic studies and preclinical hypothesis testing in CP/CPPS.
PATIENT SUMMARY: In this study, we established a prostatitis-like model in C57BL/6N mice. Booster immunization with DPT+BCG induced inflammatory and pain-related changes, providing a useful model for future mechanistic studies.